Topics COVID-19 Session" jointly held by PMDA and the Pharmaceutical Manufacturers Association of Japan (PMAJ) at DIA China 2021
DIA China 2021" was held in Suzhou, China from May 20 to 23, 2021, and the Pharmaceutical Manufacturers Association of Japan (PMAJ) held a 90-minute "COVID-19 Session" in the morning of May 23 in collaboration with the Pharmaceuticals and Medical Devices Agency (PMDA).
Conference logo
On the day of the conference, the Japanese side participated online and the Chinese side participated from the DIA venue in Suzhou, China, due to the difficulties in coming and going between Japan and China caused by the new coronavirus infection.
The meeting was co-chaired by Mr. Nobumasa Nakajima, Executive Officer of the Pharmaceuticals and Medical Devices Agency (PMDA), and Ms. Shoko Nakagawa, Executive Director of the Pharmaceutical Manufacturers Association of Japan (PMAJ), and the meeting proceeded with a discussion on the Japanese pharmaceutical regulatory authority's measures against new coronavirus infection (flexibility and priority in the timing for starting clinical trials and review of products related to new coronavirus infection, free consultation on vaccines and The presentation included introductions of measures taken by both regulatory authorities (Mr. Yuji Matsukura, Assistant Director, Office of International Pharmaceutical Regulation, MHLW, and Mr. Daisuke Koga, Director, International Division, PMDA) and industry (Mr. Hirotoshi Hiyoshi, Chairman, Pharmaceutical Evaluation Committee, Pharmaceutical Manufacturers Association of Japan) on the measures against new coronavirus infection (flexibility in the start of clinical trials for products related to new coronavirus infection, priority review, and GCP/GMP inspections).
Scene of the session
The venue in Suzhou was attended by Kiyoshi Horie, Vice-Chairman of the International Committee of the Pharmaceutical Association of Japan, Hiroshi Nishiyama, China Team Leader, volunteers from the China Pharmaceuticals Committee, and about 50 people from China, as well as the R&D-based Pharmaceutical Association Committee (RDPAC), The R&D-based Pharmaceutical Association Committee (RDPAC) of the China Association of Foreign Investment Companies also provided constructive comments and evaluations.
The venue
Finally, I would like to take this opportunity to thank everyone involved for their efforts in organizing the joint session at DIA China, which was the first attempt by the Pharmaceutical Association of Japan.
( Yumiko Kobayashi, Kota Suzuki, Hiroshi Nishiyama, and Kiyoshi Horie, China Team, Asia Division, International Committee)